Botiga on-line 2.0 : ad. web i comerç electrònic en entorns de programari lliure

El present projecte tracta de la realització d'una botiga on­line amb característiques Web 2.0 utilitzant en tot moment solucions de programari lliure. La solució triada per a la implementació del nostre projecte descarta el desenvolupament total i complet del projecte, és a dir la realització d'una web programada totalment a mida, i passa per l'adaptació d'un CMS (programa per a l'administració i gestió dels continguts d'una web) als requisits de la nostra botiga.

Preserving memories on-line : the exhibition 'Memories of our childhood' and the Catalan Immigration History Museum

Gràcies a la introducció d'Internet, les institucions de la memòria poden anar ara un pas endavant i proporcionar narratives i documentació en línia. La present comunicació intenta descobrir com poden ser utilitzades les memòries en línia basant-se en dues experiències: una exposició de nens de la guerra i un portal d'immigració.

Disseny i implementació d'un sistema de gestió de la base de dades de la Colla Castellers Xiquets de Tarragona

El present treball de final de carrera té com a objectiu el disseny i la implementació d'un sistema de gestió d'una base de dades que cobreixi les necessitats de la Colla Castellers Xiquets de Tarragona. Aquestes necessitats son, en termes generals, que la base de dades pugui recollir d'una forma ordenada i eficient les dades del cens social i casteller així com tots aquells ens que siguin d'interès per als Xiquets de Tarragona. A la vegada, també es vol que aquesta informatització se li tregui un rendiment, sent capaç de realitzar les diferents gestions que pot tenir una entitat d'aquestes característiques.

Disseny i implementació de la base de dades d'un sistema de control energètic

La Comunitat Europea ha encarregat el disseny i implementació d'una base de dades que ajudi a controlar el consum energètic i estudiar les seves característiques. Aquest TFC conté el desenvolupament d'aquest projecte començant des de zero i contempla totes les fases de creació de la base de dades a implementar en Oracle. Les fases del projecte són: anàlisi prèvia, anàlisi de requisits, disseny, implementació, proves i lliurament final.

Disseny i implementació d'una base de dades relacional per a una empresa de selecció de personal

Anàlisi, disseny i implementació d'una base de dades relacional i un magatzem de dades per a una empresa de selecció de personal.

Disseny i implementació de la base de dades d'un sistema de control energètic

Aquest treball de fi de carrera consisteix en la realització d'una base de dades per a la gestió de recursos energètics i el seu control de distribució i consum.

Disseny i implementació de la base de dades d'un sistema de control energètic

Donada la necessitat a nivell europeu d'aconseguir un control energètic, la Comunitat Europea vol implementar una aplicació que permeti la generació de dades estadístiques de l'ús de l'energia. El projecte consisteix en desenvolupar la primera fase d'aquesta aplicació: una base de dades que permeti emmagatzemar tota la informació necessària per la generació de dades estadístiques sobre l'ús de l'energia. A nivell general, la funció de la Base de Dades ha de ser la de guardar tota la informació necessària per entendre i fer actuacions per millorar el consum energètic, així com per a guardar l'històric del mateix. De la mateixa manera, ha de permetre guardar la informació dels clients, comptadors, centraletes de distribució, centrals de producció, etc., permitint realitzar amb aquesta informació diferents consultes habituals com el consum mig de tots els clients, la línia que ha estat més carregada a nivell d'energia consumida, etc.

Disseny i implementació de la base de dades d'un sistema de control energètic

El treball proposat consisteix en implementar un sistema de base de dades per donar resposta a una necessitat de control energètic que s'ha plantejat a nivell europeu. Inclou fase de plantejament, disseny, implementació i proves.

Disseny i implementació de la base de dades d'un sistema de control energètic

Proyecto de base de datos para un sistema de control energético para la Comunidad Europea que incluye la gestión de centrales, contadores y consumos.

Disseny i implementació de la base de dades d'un sistema de control energètic

Disseny d'un model de base de dades relacional, juntament amb els procediments i disparadors necessaris per controlar un sistema energètic.

Granada Virus: a Natural Phlebovirus Reassortant of the Sandfly Fever Naples Serocomplex with Low Seroprevalence in Humans

A new member of the phlebovirus genus, tentatively named Granada virus, was detected in sandflies collected in Spain. By showing the presence of specific neutralizing antibodies in human serum collected in Granada, we show that Granada virus infects humans. The analysis of the complete genome of Granada virus revealed that this agent is likely to be a natural reassortant of the recently described Massilia virus (donor of the long and short segments) with ayet unidentified phlebovirus (donor of the medium segment)

Local delivery of glial cell line-derived neurotrophic factor improves facial nerve regeneration after late repair.

OBJECTIVES/HYPOTHESIS: Facial nerve regeneration is limited in some clinical situations: in long grafts, by aged patients, and when the delay between nerve lesion and repair is prolonged. This deficient regeneration is due to the limited number of regenerating nerve fibers, their immaturity and the unresponsiveness of Schwann cells after a long period of denervation. This study proposes to apply glial cell line-derived neurotrophic factor (GDNF) on facial nerve grafts via nerve guidance channels to improve the regeneration. METHODS: Two situations were evaluated: immediate and delayed grafts (repair 7 months after the lesion). Each group contained three subgroups: a) graft without channel, b) graft with a channel without neurotrophic factor; and c) graft with a GDNF-releasing channel. A functional analysis was performed with clinical observation of facial nerve function, and nerve conduction study at 6 weeks. Histological analysis was performed with the count of number of myelinated fibers within the graft, and distally to the graft. Central evaluation was assessed with Fluoro-Ruby retrograde labeling and Nissl staining. RESULTS: This study showed that GDNF allowed an increase in the number and the maturation of nerve fibers, as well as the number of retrogradely labeled neurons in delayed anastomoses. On the contrary, after immediate repair, the regenerated nerves in the presence of GDNF showed inferior results compared to the other groups. CONCLUSIONS: GDNF is a potent neurotrophic factor to improve facial nerve regeneration in grafts performed several months after the nerve lesion. However, GDNF should not be used for immediate repair, as it possibly inhibits the nerve regeneration.

Mutation analysis of genes that control the G1/S cell cycle in melanoma: TP53, CDKN1A, CDKN2A, and CDKN2B.

BACKGROUND The role of genes involved in the control of progression from the G1 to the S phase of the cell cycle in melanoma tumors in not fully known. The aim of our study was to analyse mutations in TP53, CDKN1A, CDKN2A, and CDKN2B genes in melanoma tumors and melanoma cell lines METHODS We analysed 39 primary and metastatic melanomas and 9 melanoma cell lines by single-stranded conformational polymorphism (SSCP). RESULTS The single-stranded technique showed heterozygous defects in the TP53 gene in 8 of 39 (20.5%) melanoma tumors: three new single point mutations in intronic sequences (introns 1 and 2) and exon 10, and three new single nucleotide polymorphisms located in introns 1 and 2 (C to T transition at position 11701 in intron 1; C insertion at position 11818 in intron 2; and C insertion at position 11875 in intron 2). One melanoma tumor exhibited two heterozygous alterations in the CDKN2A exon 1 one of which was novel (stop codon, and missense mutation). No defects were found in the remaining genes. CONCLUSION These results suggest that these genes are involved in melanoma tumorigenesis, although they may be not the major targets. Other suppressor genes that may be informative of the mechanism of tumorigenesis in skin melanomas should be studied.

Y-90 Ibritumomab Tiuxetan (Zevalin (R)) Consolidation of First Remission In Advanced Stage Follicular Non Hodgkin's Lymphoma Updated Results After a Median Follow up of 662 Months From the International, Randomized, Phase III First Line Indolent Trial (FIT) In 414 Patients

The FIT trial was conducted to evaluate the safety and efficacy of 90Y-ibritumomab tiuxetan (0.4 mCi/kg; maximum dose 32 mCi) when used as consolidation of first complete or partial remission in patients with previously untreated, advanced-stage follicular lymphoma (FL). Patients were randomly assigned to either 90Y-ibritumomab treatment (n = 207) or observation (n = 202) within 3 months (mo) of completing initial induction therapy (chemotherapy only: 86%; rituximab in combination with chemotherapy: 14%). Response status prior to randomization did not differ between the groups: 52% complete response (CR)/CR unconfirmed (CRu) to induction therapy and 48% partial response (PR) in the 90Y-ibritumomab arm vs 53% CR/CRu and 44% PR in the control arm. The primary endpoint was progression-free survival (PFS) of the intent-to-treat (ITT) population. Results from the first extended follow-up after a median of 3.5 years revealed a significant improvement in PFS from the time of randomization with 90Y-ibritumomab consolidation compared with control (36.5 vs 13.3 mo, respectively; P < 0.0001; Morschhauser et al. JCO. 2008; 26:5156-5164). Here we report a median follow-up of 66.2 mo (5.5 years). Five-year PFS was 47% in the 90Y-ibritumomab group and 29% in the control group (hazard ratio (HR) = 0.51, 95% CI 0.39-0.65; P < 0.0001). Median PFS in the 90Y-ibritumomab group was 49 mo vs 14 mo in the control group. In patients achieving a CR/CRu after induction, 5-year PFS was 57% in the 90Y-ibritumomab group, and the median had not yet been reached at 92 months, compared with a 43% 5-year PFS in the control group and a median of 31 mo (HR = 0.61, 95% CI 0.42-0.89). For patients in PR after induction, the 5-year PFS was 38% in the 90Y-ibritumomab group with a median PFS of 30 mo vs 14% in the control group with a median PFS of 6 mo (HR = 0.38, 95% CI 0.27-0.53). Patients who had received rituximab as part of induction treatment had a 5-year PFS of 64% in the 90Y-ibritumomab group and 48% in the control group (HR = 0.66, 95% CI 0.30-1.47). For all patients, time to next treatment (as calculated from the date of randomization) differed significantly between both groups; median not reached at 99 mo in the 90Y-ibritumomab group vs 35 mo in the control group (P < 0.0001). The majority of patients received rituximab-containing regimens when treated after progression (63/82 [77%] in the 90Y-ibritumomab group and 102/122 [84%] in the control group). Overall response rate to second-line treatment was 79% in the 90Y-ibritumomab group (57% CR/CRu and 22% PR) vs 78% in the control arm (59% CR/CRu, 19% PR). Five-year overall survival was not significantly different between the groups; 93% and 89% in the 90Y-ibritumomab and control groups, respectively (P = 0.561). To date, 40 patients have died; 18 in the 90Y-ibritumomab group and 22 in the control group. Secondary malignancies were diagnosed in 16 patients in the 90Y-ibritumomab arm vs 9 patients in the control arm (P = 0.19). There were 6 (3%) cases of myelodysplastic syndrome (MDS)/acute myelogenous leukemia (AML) in the 90Y-ibritumomab arm vs 1 MDS in the control arm (P = 0.063). In conclusion, this extended follow-up of the FIT trial confirms the benefit of 90Y-ibritumomab consolidation with a nearly 3 year advantage in median PFS. A significant 5-year PFS improvement was confirmed for patients with a CR/CRu or a PR after induction. Effective rescue treatment with rituximab-containing regimens may explain the observed no difference in overall survival between both patient groups who were - for the greater part - rituximab-naïve.